ArticleAnnals of surgical oncology2026
Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate outcome for patients affected by primary retroperitoneal sarcomas (RPS) treated over time at a single large referral institution.
methodsThe study included all consecutive patients with primary, localized, adult-type soft tissue sarcoma of the retroperitoneum observed and treated at the authors' institution from January 2002 to December 2021. The primary endpoint was overall survival (OS). The secondary endpoints were crude cumulative incidence (CCI) of local recurrence (LR) and distant metastases (DM), and post-recurrence OS. Based on the date of primary surgery, the patients were divided in two groups (2002-2011 and 2012-2021).
resultsThe study identified 872 patients: 244 treated between 2002 and 2011 (early cohort) and 628 treated between 2012 and 2021 (recent cohort). The median follow-up period was 77.1 months (interquartile range [IQR], 41.7-115.4): 136.7 months (IQR, 118.1-166.4 months) for the early cohort and 59.5 months (IQR, 34.1-88.9 months) for the recent cohort. At the multivariable analysis, the patients in the recent cohort had significantly better OS. The early cohort had a 5 year OS of 61.7% (95% CI, 55.9-68.2%) and a 10 year OS of 47.7% (95% CI, 41.7-54.6%), whereas the recent cohort had a 5 year OS of 78.8% (95% CI, 75.1-82.6%) and a 10 year OS of 64.0% (95% CI, 57.8-70.8%). The recent cohort had fewer distant metastases (hazard ratio [HR], 1.50; 95% CI, 1.06-2.11; p = 0.022) and a similar rate of local recurrences (HR, 1.31; 95% CI, 0.97-1.76; p = 0.080). The 30 month post-recurrence OS was 41.9% (95% CI, 34.5-50.9%) in the early cohort and 65.9% (95% CI, 59.5-72.9%) in the recent cohort (p < 0.001).
conclusionsManagement of RPS in the recent years has resulted in prolonged OS. These findings establish new standards for historical comparisons of emerging strategies.
Indexed as
Identifiers
41390553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.